Session : Proffered Paper session – Gynaecological cancers

Channel 3 Friday, 17 September, 08:30—09:50

Presentation LBA33 : Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Presentation LBA32 : Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Presentation 722º : Randomised Phase II Trial of Olaparib compared to weekly paclitaxel or Olaparib plus Cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)



Session: Presidential symposium 1 – Gynaecological cancers

Channel 1 Saturday, 18 September, 10:05—11:35
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study



Session: Mini oral session – Gynaecological cancers

Channel 5 Sunday, 19 September, 12:30—13:30

Presentation 726MO : Outcomes by Histology and Prior Therapy With Lenvatinib Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer (Study 309/KEYNOTE-775)

Presentation 795MO : Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): updated results from KEYNOTE-158